pSivida Corp Announces Fourth Quarter and Fiscal Year 2010 Financial Results Release Date and Conference Call Information
15 September 2010 - 7:20PM
Business Wire
pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leader in the
development of sustained release drug delivery systems for
difficult-to-treat, back-of-the-eye conditions, today announced
that its financial results for the fourth quarter and fiscal year
2010 will be released after market close on Wednesday, September
22, 2010, followed the same day by a conference call and live
webcast scheduled for 4:30 p.m. ET.
The conference call may be accessed by dialing (866) 730-5764
from the U.S. and Canada, or (857) 350-1588 from international
locations, passcode 99650578. A replay of the call will be
available approximately two hours following the end of the call
through September 29, 2010. The replay may be accessed by dialing
(888) 286-8010 within the U.S. and Canada or (617) 801-6888 from
international locations, passcode 60197831.
The conference call will be available via the Internet at
www.psivida.com and will also be distributed through the Thomson
StreetEvents Network. Individual investors can listen to the call
via www.earnings.com and Institutional investors can access the
call via www.streetevents.com. Listeners are encouraged to login at
least 15 minutes prior to the start of the scheduled presentation
to register, download and install any necessary audio software. The
call will be archived and accessible on the Web site for
approximately 30 days.
About pSivida Corp.
pSivida Corp is a leader in the development of tiny, sustained
release, drug delivery products and technologies that are
administered by implantation, insertion or injection. The Company
uses these systems to develop treatments for serious, unmet,
medical needs. pSivida's intellectual property portfolio consists
of over 50 patent families, more than 100 granted patents,
including patents accepted for issuance, and more than 150 patent
applications. pSivida conducts its operations from Boston in the
United States and Malvern in the United Kingdom.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995: Various statements made in this
release are forward-looking, and are inherently subject to risks,
uncertainties and potentially inaccurate assumptions. All
statements that address activities, events or developments that we
intend, expect or believe may occur in the future are
forward-looking statements. The following are some of the factors
that could cause actual results to differ materially from the
anticipated results or other expectations expressed, anticipated or
implied in our forward-looking statements: maintaining
collaboration agreements with Alimera and Pfizer; modifications of
existing terms of collaboration agreements with Alimera and Pfizer;
achievement of milestones and other contingent contractual events;
ability to prove safety and efficacy of, and achieve regulatory
approvals for, and successfully commercialize Iluvien, BrachySil
and other products; ability to raise capital; ability to achieve
profitability; ability to derive revenues from Retisert; ability to
develop new products; impairment of intangibles; fluctuations in
the fair values of certain outstanding warrants; fluctuations in
operating results; termination of license agreements; ability to
obtain partners to develop and market products; competition; extent
of third-party reimbursement for products; product liability;
ability to protect intellectual property or infringement of others'
intellectual property; retention of key personnel; consolidation in
the pharmaceutical and biotechnology industries; compliance with
laws; maintaining effective internal control over financial
reporting; manufacturing risks; risks and costs of international
business operations; volatility of stock price; possible dilution
through exercise of outstanding warrants and stock options or
future stock issuances; possible influence by Pfizer; ability to
pay any registration penalties; and other factors described in our
filings with the Securities and Exchange Commission. Given these
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements. Our forward-looking statements
speak only as of the dates on which they are made. We do not
undertake any obligation to publicly update or revise our
forward-looking statements even if experience or future changes
makes it clear that any projected results expressed or implied in
such statements will not be realized.
For more information on pSivida, visit www.psivida.com.
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024